350 related articles for article (PubMed ID: 33654227)
21. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
22. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies.
Alviano AM; Biondi M; Grassenis E; Biondi A; Serafini M; Tettamanti S
Front Immunol; 2024; 15():1407992. PubMed ID: 38887285
[TBL] [Abstract][Full Text] [Related]
23. Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Zheng S; Asnani M; Thomas-Tikhonenko A
Cancer J; 2019; 25(3):217-222. PubMed ID: 31135529
[TBL] [Abstract][Full Text] [Related]
24. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M; Bobisse S; Chiffelle J; Harari A
Front Immunol; 2021; 12():701636. PubMed ID: 34394096
[TBL] [Abstract][Full Text] [Related]
25. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
26. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.
Bridgeman JS; Ladell K; Sheard VE; Miners K; Hawkins RE; Price DA; Gilham DE
Clin Exp Immunol; 2014 Feb; 175(2):258-67. PubMed ID: 24116999
[TBL] [Abstract][Full Text] [Related]
27. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
28. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Biernacki MA; Brault M; Bleakley M
Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
[TBL] [Abstract][Full Text] [Related]
29. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
Karahan ZS; Aras M; Sütlü T
Turk J Haematol; 2023 Feb; 40(1):1-10. PubMed ID: 36719099
[TBL] [Abstract][Full Text] [Related]
30. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
31. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
32. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
33. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
34. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
35. Developing neoantigen-targeted T cell-based treatments for solid tumors.
Yamamoto TN; Kishton RJ; Restifo NP
Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
[TBL] [Abstract][Full Text] [Related]
36. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
37. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
39. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P; Kelly LM; Hoyos V
Front Immunol; 2022; 13():835762. PubMed ID: 35309357
[TBL] [Abstract][Full Text] [Related]
40. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.
Salzer B; Schueller CM; Zajc CU; Peters T; Schoeber MA; Kovacic B; Buri MC; Lobner E; Dushek O; Huppa JB; Obinger C; Putz EM; Holter W; Traxlmayr MW; Lehner M
Nat Commun; 2020 Aug; 11(1):4166. PubMed ID: 32820173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]